Berenberg Bank Reiterates Buy Rating for Hikma Pharmaceuticals (LON:HIK)

Key Points

• Berenberg Bank reiterated a Buy rating on Hikma with a GBX 1,800 price target, implying about a 30.48% upside from the current share price.
• Deutsche Bank trimmed its target to GBX 2,400 but maintained a Buy, and five analysts in total rate the stock a Buy with an average target of GBX 2,226.
• Hikma opened at GBX 1,379.50, trading in a 12‑month range of GBX 1,187–2,164, with a market cap of £2.98 billion and a P/E of 7.62.

Hikma Pharmaceuticals (LON:HIK - Get Free Report)'s stock had its "buy" rating reaffirmed by analysts at Berenberg Bank in a research note issued on Tuesday,Digital Look reports. They presently have a GBX 1,800 price target on the stock. Berenberg Bank's price target would suggest a potential upside of 30.48% from the company's current price.

Separately, Deutsche Bank Aktiengesellschaft reduced their target price on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a "buy" rating on the stock in a research note on Friday, January 9th. Five equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Hikma Pharmaceuticals currently has a consensus rating of "Buy" and an average target price of GBX 2,226.

Hikma Pharmaceuticals Stock Performance

LON:HIK opened at GBX 1,379.50 on Tuesday. Hikma Pharmaceuticals has a twelve month low of GBX 1,187 and a twelve month high of GBX 2,164. The company has a market capitalization of £2.98 billion, a P/E ratio of 7.62, a price-to-earnings-growth ratio of 2.38 and a beta of 0.61. The company has a current ratio of 1.82, a quick ratio of 1.27 and a debt-to-equity ratio of 63.59. The firm has a 50-day moving average price of GBX 1,335.54 and a two-hundred day moving average price of GBX 1,509.57.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.